MAAT INDEX

CLAIM #56404 · Thermo Fisher Scientific Inc (TMO) · 2024Q1 earnings call · Apr 24, 2024 · due Dec 31, 2024

Full year average diluted share count is assumed to be approximately 383 million shares.

Stephen Williamson · CFO

CANNOT_DETERMINE
versus commitment · official band 5 percent
Committed
Full year average diluted share count is assumed to be approximately 383 million shares.
Reported
Average diluted shares were 383 million in Q4, 5 million lower year-over-year, driven by share repurchases net of option dilution.

How to check this claim

Look at: Full year average diluted share count outstanding, fiscal year 2024

It came true if: Full year average diluted shares between 378 million and 388 million

Where: Company income statement / 10-K diluted share count disclosure

In context

revenue. We see that FX will be roughly neutral year-over-year to both revenue and adjusted EPS. Given recent FX rate changes, we're assuming that the $0.07 beat that we saw in Q1 is offset in the remainder of the year, leading to no change for the year as a whole for FX versus our prior guide. We expect the adjusted income tax rate will be 10.5% in 2024. And we're assuming between $1.3 billion and $1.5 billion of net capital expenditures and free cash flow in the range of $6.5 billion to $7 billion. In terms of capital deployment. We're assuming $3 billion of share buybacks, which were completed in January. We expect to return approximately $600 million of capital to shareholders this year through dividends, we continue to see [ we will close ] the Olink acquisition by midyear. Full year average diluted share count is assumed to be approximately 383 million shares. And finally, I wanted to touch on quarterly phasing. In Q2, we expect revenue dollars to step up from the first quarter, and organic growth will likely be 2 points better than Q1. And we expect Q2 adjusted EPS to be similar to Q1. This reflects the revised view of the phasing of spending within the year that I mentioned. I think this view of Q2 is pretty close to what's currently baked into consensus right now. So to conclude. We delivered on our commitments in Q1, and we're in a great position to deliver differentiated performance for all our stakeholders in 2024. With that, I'll turn the call back over to Raf. Rafael Tejada: Operator, we're ready for the Q&A portion of the call. Operator: [Operator Instructions] We have the first question from Doug Schenkel with Wolfe Researc

Verify independently

SEC filings for TMO · Claim quote is verbatim from the 2024Q1 earnings call.